X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ALKEM LABORATORIES - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ALKEM LABORATORIES NOVARTIS/
ALKEM LABORATORIES
 
P/E (TTM) x 392.7 - - View Chart
P/BV x 19.3 7.6 252.9% View Chart
Dividend Yield % 1.5 0.6 263.3%  

Financials

 NOVARTIS   ALKEM LABORATORIES
EQUITY SHARE DATA
    NOVARTIS
Mar-16
ALKEM LABORATORIES
Mar-16
NOVARTIS/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9821,589 61.8%   
Low Rs5561,232 45.1%   
Sales per share (Unadj.) Rs252.9417.5 60.6%  
Earnings per share (Unadj.) Rs62.156.3 110.4%  
Cash flow per share (Unadj.) Rs63.364.7 97.8%  
Dividends per share (Unadj.) Rs10.0012.70 78.7%  
Dividend yield (eoy) %1.30.9 144.4%  
Book value per share (Unadj.) Rs363.6292.9 124.1%  
Shares outstanding (eoy) m31.96119.57 26.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.03.4 90.0%   
Avg P/E ratio x12.425.1 49.4%  
P/CF ratio (eoy) x12.221.8 55.7%  
Price / Book Value ratio x2.14.8 43.9%  
Dividend payout %16.122.6 71.3%   
Avg Mkt Cap Rs m24,580168,653 14.6%   
No. of employees `0000.8NA-   
Total wages/salary Rs m1,8019,171 19.6%   
Avg. sales/employee Rs Th10,748.9NM-  
Avg. wages/employee Rs Th2,395.2NM-  
Avg. net profit/employee Rs Th2,641.1NM-  
INCOME DATA
Net Sales Rs m8,08349,915 16.2%  
Other income Rs m8291,645 50.4%   
Total revenues Rs m8,91351,561 17.3%   
Gross profit Rs m2348,482 2.8%  
Depreciation Rs m371,006 3.6%   
Interest Rs m2671 0.3%   
Profit before tax Rs m1,0258,451 12.1%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7521,606 46.8%   
Profit after tax Rs m1,9866,731 29.5%  
Gross profit margin %2.917.0 17.1%  
Effective tax rate %73.419.0 386.0%   
Net profit margin %24.613.5 182.2%  
BALANCE SHEET DATA
Current assets Rs m12,67827,062 46.8%   
Current liabilities Rs m2,43315,324 15.9%   
Net working cap to sales %126.723.5 539.0%  
Current ratio x5.21.8 295.1%  
Inventory Days Days3367 49.2%  
Debtors Days Days2241 54.5%  
Net fixed assets Rs m6912,610 0.5%   
Share capital Rs m160239 66.8%   
"Free" reserves Rs m11,46034,490 33.2%   
Net worth Rs m11,62135,027 33.2%   
Long term debt Rs m01,212 0.0%   
Total assets Rs m14,40054,387 26.5%  
Interest coverage x570.513.6 4,194.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.9 61.2%   
Return on assets %13.813.6 101.4%  
Return on equity %17.119.2 88.9%  
Return on capital %23.624.9 94.8%  
Exports to sales %0.712.9 5.8%   
Imports to sales %18.63.1 602.4%   
Exports (fob) Rs m606,461 0.9%   
Imports (cif) Rs m1,5031,540 97.6%   
Fx inflow Rs m1866,563 2.8%   
Fx outflow Rs m1,8213,012 60.5%   
Net fx Rs m-1,6353,552 -46.0%   
CASH FLOW
From Operations Rs m2,5317,259 34.9%  
From Investments Rs m-8,2701,864 -443.6%  
From Financial Activity Rs m-386-9,273 4.2%  
Net Cashflow Rs m-6,125-150 4,083.0%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 33.1 6.0%  
FIIs % 1.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 0.0 -  
Shareholders   41,647 68,381 60.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Sensex Touching New Highs, Takeaways from Acquisition of HPCL and Top Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,798 yesterday. Considering a span of one year, the benchmark index has delivered a 32% return.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 22, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS